Avrobio Inc (DELISTED) (AVRO:DL)
16.80
-0.24
(-1.41%)
USD |
NASDAQ |
Jun 20, 16:00
Avrobio Enterprise Value: -27.63M for June 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 20, 2024 | -27.63M |
| June 18, 2024 | -26.73M |
| June 17, 2024 | -24.94M |
| June 14, 2024 | -26.28M |
| June 13, 2024 | -24.49M |
| June 12, 2024 | -23.14M |
| June 11, 2024 | -23.59M |
| June 10, 2024 | -24.04M |
| June 07, 2024 | -22.24M |
| June 06, 2024 | -24.94M |
| June 05, 2024 | -25.48M |
| June 04, 2024 | -26.28M |
| June 03, 2024 | -24.49M |
| May 31, 2024 | -24.04M |
| May 30, 2024 | -25.83M |
| May 29, 2024 | -24.49M |
| May 28, 2024 | -24.04M |
| May 24, 2024 | -22.69M |
| May 23, 2024 | -27.18M |
| May 22, 2024 | -27.63M |
| May 21, 2024 | -28.53M |
| May 20, 2024 | -28.08M |
| May 17, 2024 | -28.08M |
| May 16, 2024 | -28.08M |
| May 15, 2024 | -28.98M |
| Date | Value |
|---|---|
| May 14, 2024 | -32.57M |
| May 13, 2024 | -29.88M |
| May 10, 2024 | -35.26M |
| May 09, 2024 | -34.36M |
| May 08, 2024 | -33.92M |
| May 07, 2024 | -34.36M |
| May 06, 2024 | -34.81M |
| May 03, 2024 | -35.71M |
| May 02, 2024 | -35.26M |
| May 01, 2024 | -35.72M |
| April 30, 2024 | -37.06M |
| April 29, 2024 | -37.06M |
| April 26, 2024 | -36.17M |
| April 25, 2024 | -37.30M |
| April 24, 2024 | -37.07M |
| April 23, 2024 | -36.17M |
| April 22, 2024 | -36.62M |
| April 19, 2024 | -36.62M |
| April 18, 2024 | -34.83M |
| April 17, 2024 | -35.72M |
| April 16, 2024 | -33.93M |
| April 15, 2024 | -33.93M |
| April 12, 2024 | -33.48M |
| April 11, 2024 | -33.48M |
| April 10, 2024 | -34.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-118.31M
Minimum
Mar 07 2022
673.96M
Maximum
Feb 11 2020
117.62M
Average
-8.014M
Median
May 30 2023
Enterprise Value Benchmarks
| Agenus Inc | 289.55M |
| BioCryst Pharmaceuticals Inc | 1.822B |
| AIM ImmunoTech Inc | 13.92M |
| Protalix BioTherapeutics Inc | 48.91M |
| Armata Pharmaceuticals Inc | 190.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.808M |
| Total Expenses (Quarterly) | 7.941M |
| EPS Diluted (Quarterly) | -1.80 |
| Earnings Yield | 49.29% |